tbuckley/cabot-search huggingface dataset:
Surgical technique and clinical results of one- or two-stage laparoscopic right hemihepatectomy after portal vein embolization in patients with initially unresectable colorectal liver metastases: A case series
Authors: Burak Görgec, Amal Suhool, Ra'ed Al-Jarrah, Martina Fontana, Nadeem A. Tehami, Sachin Modi, Mohammad Abu Hilal
Journal: International Journal of Surgery (2020)
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy
Authors: J. Haanen, M.S. Ernstoff, Y. Wang, A.M. Menzies, I. Puzanov, P. Grivas, J. Larkin, S. Peters, J.A. Thompson, M. Obeid
Journal: Annals of Oncology (2020)
Multimodality treatment in retroperitoneal sarcoma
Authors: L. N. Minea, R. Anghel, D. Stanculeanu, T. Georgescu, X. Bacinschi, A. Tarlea, L. Oprea, C. Negrei, M. Barna, C. Gheta
Journal: Journal of Clinical Oncology (2006)

9579 Background: Soft tissue sarcomas account for less than 1% of all malignancies; 10% of them arise in the retroperitoneal tissues. Surgical resection is considered as the most important treatment but it is often difficult to perform because of late presentation, anatomical conditions and invasion of adjacent structures. Adjuvant treatments have limited efficacy. Methods: We evaluate two year survival rate and safety profile of multimodal treatment in retroperitoneal sarcomas. Between Jan 1999 - Dec 2003, 37 patients with retroperitoneal sarcomas were treated in our institution. Median age 48.2 years (range 20 - 70), sex ratio M:F - 15:22, PS ECOG 0:1:2 - 25:8:4, tumor grading G1:G2:G3 - 8:14:15. Surgery was performed in 34 cases (29 complete resection, 5 partial resection) and 3 patients were only biopsied. All the patients received adjuvant radiochemotherapy and 4 more chemotherapy cycles thereafter. The chemotherapy regimen consisted of Ifosfamide 1,500 mg/sqm/day day 1–5 with mesna uroprotection and Epirubicin 50 mg/sqm day 1, repeated on days 29–33 during RT. They received external beam RT up to 45 - 50 Gy, conventional fractionation. The Ifosfamide and Epirubicin doses were increased at 1,800 mg/sqm and 75 mg/sqm respectively after chemoradiotherapy if no grade 3–4 toxicities occurred. Results: The overall 2 year survival rate was 70.27%. The 2 year survival rate was 100% - 71.43% - and 53.33% for G1, G2 and G3 tumors respectively; the figures are 82.75% - 40% and 0% for complete resection, partial resection and diagnostic biopsy respectively. All patients received the intended treatment. There were only 8 cycle delays for grade 3 toxicities. 6 patients had grade 3–4 hematological toxicities and 4 patients had grade 3–4 digestive toxicities. Retroperitoneal fibrosis occurred in 3 cases. Conclusions: This combined modality treatment can be successfully delivered. We have no major toxicities. We obtained similar results as cited in the literature. Better results could be obtained with newer radiation techniques (conformal RT or IMRT). No significant financial relationships to disclose.
Long-term follow-up and compilation of two trials utilizing concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy (RT) in patients with localized esophageal cancer involved in the Minnie Pearl Cancer Research Network
Authors: A. A. Meluch, F. A. Greco, D. R. Spigel, J. R. Gray, M. Thomas, C. Meng, J. D. Bearden, S. H. Rosenoff, R. C. Hermann, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2006)

4028 Background: The role of preoperative chemoradiation in patients (pts) with localized esophageal cancer remains unclear. Most preoperative regimens produce 20–30% pathologic complete response (pCR) rates, which predicts improved survival. Our community-based multicenter group performed sequential trials evaluating a novel paclitaxel-containing preoperative chemoradiation regimen, now with median followup &gt; 6 years. Methods: Eligibility: untreated adenocarcinoma or squamous carcinoma of esophagus or GE junction; clinical stage I-III; surgical candidate; ECOG PS 0–2, adequate organ function; informed consent. Pts received paclitaxel 200mg/m 2 IV and carboplatin AUC 6.0 IV, days 1, 22; 5FU 225mg/m 2 , 24 hr continuous infusion, days 1–42; RT 45 Gy in 1.8 Gy/d single daily fractions. Surgical resection was performed 6–10 weeks after completion. Results: 226 pts with the following characterstics were treated: median age 58 years; adenocarcinoma 74%; distal/GE junction 79%; clinical stage II/III 84%. 220 pts (97%) completed preoperative therapy, and 199 pts (88%) had resection. Responses in resected pts: pCR 45% (39% of entire group), PR (microscopic residual) 29%, PR (macroscopic) 15%. After median followup of 75 months, median PFS and overall survival for the entire group were 19 and 26 months, respectively; 3- and 5-year survivals were 40% and 33%, respectively. Median survival was better in pts with pCR vs others (33 vs 21 mo; p=.026). 3-yr survival comparisons of other potential prognostic factors: adeno vs squamous, 43% vs 42%; clinical stage I vs II/III, 63% vs 36% (p=.001); distal location vs others, 38% vs 45% (p=.45). Toxicity data have been previously published; overall 13 pts (6%) had treatment-related death (preop 2, postop 11). Conclusions: This preoperative combined modality regimen was feasible and highly active in a community-based setting. This is one of the largest series of patients treated with an identical preoperative approach and with long-term followup is curative in one-third of pts with localized esophageal cancer. [Table: see text]
In high-risk ICU patients, early palliative care consultation increased transition to DNR/DNI status
Authors: Saraschandra Vallabhajosyula, Cory Ingram
Journal: Annals of Internal Medicine (2020)

ACP Journal Club17 March 2020In high-risk ICU patients, early palliative care consultation increased transition to DNR/DNI statusSaraschandra Vallabhajosyula, MD, Cory Ingram, MDSaraschandra Vallabhajosyula, MDMayo Clinic, Rochester, Minnesota, USA (S.V., C.I.)Search for more papers by this author, Cory Ingram, MDMayo Clinic, Rochester, Minnesota, USA (S.V., C.I.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202003170-030 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationMa J, Chi S, Buettner B, et al. Early palliative care consultation in the medical ICU: a cluster randomized crossover trial. Crit Care Med. 2019;47:1707-15. https://pubmed.ncbi.nlm.nih.gov/31609772Clinical Impact RatingsHospitalists: Critical Care: References1 Vallabhajosyula S, Prasad A, Dunlay SM, et al. Utilization of palliative care for cardiogenic shock complicating acute myocardial infarction: a 15-year national perspective on trends, disparities, predictors, and outcomes. J Am Heart Assoc. 2019;8:e011954. [PMID: 31315497] Google Scholar2 Aslakson RA, Curtis JR, Nelson JE. The changing role of palliative care in the ICU. Crit Care Med. 2014;42:2418-28. [PMID: 25167087] Google Scholar3 Kamal AH, Bull JH, Swetz KM, et al. Future of the palliative care workforce: preview to an impending crisis. Am J Med. 2017;130:113-4. [PMID: 27687068] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mayo Clinic, Rochester, Minnesota, USA (S.V., C.I.)Disclosures: The commentators have disclosed no conflicts of interest. The forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3040.This article was published at Annals.org on 3 March 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byManagerial and organisational prerequisites for the integration of palliative care in the intensive care setting: A qualitative studyDNR and COVID-19: The Ethical Dilemma and Suggested Solutions 17 March 2020Volume 172, Issue 6Page: JC30KeywordsCommunication in health careDo not resuscitate ordersEmotionsHospitalsIntensive care unitsMorbidityMortalityPalliative careParkinson diseasePatients ePublished: 17 March 2020 Issue Published: 17 March 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
High-Sensitivity Cardiac Troponin I Levels and Prediction of Heart Failure
Authors: Isabell Yan, Christin S. Börschel, Johannes T. Neumann, Ngoc A. Sprünker, Nataliya Makarova, Jukka Kontto, Kari Kuulasmaa, Veikko Salomaa, Christina Magnussen, Licia Iacoviello, Augusto Di Castelnuovo, Simona Costanzo, Allan Linneberg, Stefan Söderberg, Tanja Zeller, Francisco M. Ojeda-Echevarria, Stefan Blankenberg, Dirk Westermann
Journal: JACC Heart Failure (2020)

The aims of this study were to characterize the association of high-sensitivity cardiac troponin I (hs-cTnI) with heart failure (HF), to determine its predictive value beyond classical cardiovascular risk factors (CVRFs) and N-terminal pro-B-type natriuretic peptide, and to derive a relevant cutoff for potential clinical application.HF is an important contributor to the overall burden of cardiovascular disease. Early identification of individuals at risk could be beneficial for preventive therapies.Based on the Biomarker for Cardiovascular Risk Assessment in Europe consortium, we analyzed individual-level data from 4 prospective population-based cohort studies including 48,455 individuals. Participants with myocardial infarction, HF, and stroke at baseline were excluded. We investigated the value of adding hs-cTnI to CVRFs and N-terminal pro-B-type natriuretic peptide using Cox proportional hazards survival models and for prediction by calculating C-statistics and Brier score.The median age of the study population was 51 years, and the median follow-up time for occurrence of HF was 6.61 years. Cox regression models adjusted for age, sex, and CVRFs revealed a significant association of hs-cTnI with incident HF (hazard ratio: 1.42 per log [ng/l] unit change [95% confidence interval: 1.31 to 1.53]). The best predictive value was achieved in the model with CVRFs (base model) and both biomarkers (C-index = 0.862; 95% confidence interval: 0.841 to 0.882). Optimal hs-cTnI cutoff values of 2.6 ng/l for women and 4.2 ng/l for men were derived for selecting individuals at risk.In this large dataset from the general population, hs-cTnI could show its independence for the prognosis of HF.
Association of serum CCL2 with advanced stage, metastasis, and smoking history in non-small cell lung cancer patients.
Authors: Ana Carolina Ferreira, Vladmir Claudio Cordeiro De Lima, Ludmilla Thome Chinen, Fabio Jose Haddad
Journal: Journal of Clinical Oncology (2012)

e21073 Background: Chronic exposition of respiratory tract epithelium to tobacco smoke triggers various inflammatory responses that participate in lung cancer initiation and promotion. CCL2, a CC chemokine, has been described to be involved in the lung inflammation associated with tobacco smoke exposure, and to play an important role in tumor progression and metastasis development in many solid malignancies. Methods: We prospectivelly collected blood from 165 individuals distributed in five groups: control/never smokers (64), former smokers (19), smokers (26), early stage NSCLC patients (9) and advanced stage (46). Former smokers must have stopped smoking for longer than 1 year. NSCLC diagnosis must have been confirmed histologically. Patients could not have been submitted to surgery, chemotherapy or radiotherapy, neither could have been taking corticoids, antibiotics or anticoagulants. 10ml of blood were drawn by peripheral vein puncture, using a dry Vacuntainer tube, which was kept at 37°C for 30' in a water bath. The serum was separated by centrifugation at 2000rpm, at 4 ° C, for 10 min., and frozen at 80°C. CCL2 was measured using a commercially available sandwich ELISA kit (Human CCL2 DuoSet kit, R&amp;D Systems). Median concentration of CCL2 was compared among groups using Kruskal-Wallis test, followed by a Dunn’s test. Smoking burden and serum CCL2 concentration was correlated using Spearman’s test. Median CCL2 concentration in groups associated with each clinical-demographic variable was compared using Mann-Whitney or Kruskal-Wallis test. We assumed a p value &lt;.05 to be statistically significant. Results: Serum CCL2 concentration was significantly higher in the advanced NSCLC group in comparison to the control group (p&lt;.05) and the former smokers group (p&lt;.05). Higher CCL2 levels were associated with having cancer (p=.002), metastasis (p=.025) and advanced stage disease (p=.029). No association was observed with smoking history and no correlation was observed between CCL2 level and smoking burden. Conclusions: Higher CCL2 level is associated with having NSCLC, advanced stage disease and metastasis. CCL2 concentration is not associated with smoking history or smoking burden.
Phase II study of capecitabine (X) in combination with vinorelbine (N) in patients (pts) with pretreated metastatic breast cancer (MBC)
Authors: N. Batista, L. Estevez, P. Sánchez-Rovira, A. Velasco, M. Dómine, F. Lobo, J. Oramas, J. Cruz
Journal: Journal of Clinical Oncology (2006)

10693 Background: X monotherapy is consistently effective and very well tolerated in pretreated MBC. N is also commonly used in this indication. In several studies, the combination of X + N led to response rates ranging from 43–67% in first-line MBC. As there are few data on the combination in pts with pretreated MBC, we evaluated the efficacy and safety of X + N in a multicenter phase II trial of pts previously treated with anthracycline- and taxane-containing regimens. Methods: Women &gt;18 years of age with pretreated MBC, PS 0–2 and adequate organ function were enrolled to receive a 3-weekly regimen of XN: X 1000mg/m 2 twice daily on days 1–14 and N 25mg/m 2 on days 1&amp;8, every 3 weeks up to a maximum of 6 cycles, disease progression or unacceptable toxicities. Results: A total of 32 pts were enrolled, median age 58 years (range 41–77), PS 0(74%), 1(19%), postmenopausal (61%). The most frequent sites of metastases were: liver (68%), nodes (36%), lung (36%). 58% of pts had ≥2 metastatic sites. 27 patients (87%) previously failed on anthracycline and taxane chemotherapy regimens. 152 cycles were administered with a median of 3 cycles/pt (range 1–10). Median relative dose intensity was 0.86 (0.51–1.01] for N and 0.85 (0.26–1.03] for X. All pts were evaluable for safety. The most common grade 3/4 clinical adverse events were vomiting (15%), asthenia (9%), and hand-foot syndrome (6%). Grade 3/4 hematological toxicities were: neutropenia (47%), leucopenia (9%), thrombocytopenia (3%). One pt died due to septic shock after the first cycle. 29 pts are evaluable for efficacy: the overall response rate was 52% (4 CR, 11 PR), with stable disease in 8 pts (28%). Median TTP was 7.5 months [95% CI, 5.7–9.8]. Conclusions: Our preliminary data indicate that the combination of X and N has promising clinical activity and good safety in pts with MBC who have failed prior taxane- and anthracycline-containing regimens. No significant financial relationships to disclose.
Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease
Authors: Joshua N. Curry, Matthew Saurette, Masomeh Askari, Lei Pei, Michael B. Filla, Megan R. Beggs, Peter S.N. Rowe, Timothy Fields, Andre J. Sommer, Chizu Tanikawa, Yoichiro Kamatani, Andrew P. Evan, Mehdi Totonchi, R. Todd Alexander, Koichi Matsuda, Alan S.L. Yu
Journal: Journal of Clinical Investigation (2020)

The major risk factor for kidney stone disease is idiopathic hypercalciuria. Recent evidence implicates a role for defective calcium reabsorption in the renal proximal tubule. We hypothesized that claudin-2, a paracellular cation channel protein, mediates proximal tubule calcium reabsorption. We found that claudin-2-null mice have hypercalciuria due to a primary defect in renal tubule calcium transport and papillary nephrocalcinosis that resembles the intratubular plugs in kidney stone formers. Our findings suggest that a proximal tubule defect in calcium reabsorption predisposes to papillary calcification, providing support for the vas washdown hypothesis. Claudin-2-null mice were also found to have increased net intestinal calcium absorption, but reduced paracellular calcium permeability in the colon, suggesting that this was due to reduced intestinal calcium secretion. Common genetic variants in the claudin-2 gene were associated with decreased tissue expression of claudin-2 and increased risk of kidney stones in 2 large population-based studies. Finally, we describe a family in which males with a rare missense variant in claudin-2 have marked hypercalciuria and kidney stone disease. Our findings indicate that claudin-2 is a key regulator of calcium excretion and a potential target for therapies to prevent kidney stones.
Iron metabolism and oxygen tension: effect on hypoxia inducible factor (HIF) stabilization
Authors: Jonathan Eckard, Krystyna Frenkel, Xi Huang
Journal: Cancer Research (2005)

1133  Iron is an element essential for functions of many enzymes as well as DNA synthesis in the human body. It has long been suspected that iron contributes to cancer development by oxidative DNA and protein damage, which therefore has been the focus of cancer research related to this metal. Recent studies indicate that iron is an important co-factor of HIF-prolyl hydroxylase, an enzyme involved in HIF degradation. HIF is the most recognized for controlling the regulation of an array of genes helping cells adapt to low oxygen conditions. The goal of this research has been to examine how cellular iron participates in oxygen sensing and cellular hypoxic response. We hypothesized changes in cellular iron levels during hypoxia contribute to HIF stabilization and downstream biological events. For the experiments in this study, we have used MDA-MB-231 human breast carcinoma cells as our model. We have shown that cells exposed to 1% O2 for 6 h responded with significant decreases in cellular iron bound to low molecular weight chelators (LMW-Fe;81.9 vs. 31 nmol/mg protein; p
Abstract 15171: Incidence of Ventricular Arrhythmias, Appropriate Device Therapies, and Mortality Among Patients With Cardiac Sarcoidosis With an Implantable Cardioverter Defibrillator: A Meta-Analysis
Authors: Amarnath Annapureddy, Karl E Minges, Tulasi Annapureddy, Alyssa Grimshaw, Karthik Murugiah, Jeptha P Curtis, James V Freeman, Edward J Miller
Journal: Circulation (2018)

Introduction: Cardiac sarcoidosis (CS) is associated with a poor prognosis including an increased risk of ventricular arrhythmias which often necessitates placement of an implantable cardioverter-d...
A phase I trial of weekly combination KOS-862 (Epothilone D) and trastuzumab in HER-2 overexpressing malignancies
Authors: J. Cortes, M. A. Climent, P. Gomez, A. Ruiz, E. Calvo, X. Zhang, E. S. Perez, M. Demario, J. Baselga
Journal: Journal of Clinical Oncology (2006)

2028 Background: KOS-862 (Epothilone D) (K) has shown single agent activity against metastatic breast cancer (MBC) and NSCLC. Trastuzumab (H) is standard therapy for HER-2 overexpressing MBC. This phase IB trial determined the safety and PK profile of KOS-862 in a weekly schedule with H. Methods: Eligibility: pts with HER-2 overexpressing (IHC 3+ or FISH +) chemo-refractory tumors, ECOG ≤ 2, neuropathy ≤ gr 1, no CNS metastases, and no H ≤ 6 mo. prestudy. H given as a 4 mg/kg loading dose, then 2 mg/kg wkly. K given as a 90 min iv infusion wkly × 3 Q 4 wks after H. K dose escalation cohorts: 70, 85 &amp; 100 mg/m 2 . H1 + H2 antagonists + corticosteroid prophylaxis given 30–60 min prior to K. DLT: gr 4 hematologic or gr 3 other toxicity, or toxicity requiring &gt;4 wk treatment delay. Cycle 1 + 2 PK samples obtained for K + H. Results: 13 pts treated from 9/04 - 8/05. Median age 51 yrs (36–65). All pts had MBC. Prior H therapy n = 9, prior taxane n = 11. Enrollment: 70 mg/m 2 (4), 85 mg/m 2 (3), and 100 mg/m 2 (6). Mean number cycles 3.9 (1–6). The 100 mg/m 2 cohort was expanded to 6 pts per study design; no DLTs were noted. Toxicity: Principal neurotoxicities (gr 3 noted, if present): parasthesias (10 pts, 1 gr3), neuropathic pain (5 pts, 2 gr3), dizziness (4 pts), dysguesia (4 pts), ataxia (3 pts), transient confusion (3 pts), dysesthesias (2 pts), insomnia (2 pts). No gr 4 neurotoxicities reported. Non-neurologic toxicities were limited to gr 1/2 and included diarrhea, pyrexia, abdominal and back pain, arthralgias. PK (n = 13): KOS-862 CL 21 ± 10 L/hr, V z 260 ± 110 L, T 1/2 9.8 ± 3.9 hr. Seco-metabolite was 67% ± 35% of K. At 100 mg/m 2 K dose (n = 6): C max 3.3 ± 1.1 μg/mL and AUC inf 11.0 ± 7.5 h*(g/mL). Neither K nor its seco-metabolite PK were affected by H. Responses: An 85 mg/m 2 K pt (no prior H or taxane) had confirmed PR and a 100 mg/m 2 K pt (prior taxane) had an unconfirmed PR. A 2 nd 100 mg/m 2 pt (no prior H or taxane, bone only disease) had &gt; 90% CEA reduction. Conclusions: This phase I study demonstrates feasibility of full dose wkly KOS-862 coadministration with wkly H. Treatment-related toxicities were all gr 1 / 2, except for 3 cases gr 3 paresthesias and neuropathic pain. PK of K and its principal metabolite were not affected by H. Three clinical responses were observed; a phase II trial of this combination is ongoing in minimally-pretreated MBC. [Table: see text]
Evaluation of Factors Related to Glycemic Management in Professional Cyclists With Type 1 Diabetes Over a 7-Day Stage Race
Authors: Sam N. Scott, Mark P. Christiansen, Federico Y. Fontana, Christoph Stettler, Richard M. Bracken, Charlotte A. Hayes, Miles Fisher, Bruce Bode, Peter H. Lagrou, Phil Southerland, Michael C. Riddell
Journal: Diabetes Care (2020)

OBJECTIVE To investigate factors related to glycemic management among members of a professional cycling team with type 1 diabetes over a 7-day Union Cycliste Internationale World Tour stage race. RESEARCH DESIGN AND METHODS An observational evaluation of possible factors related to glycemic management and performance in six male professional cyclists with type 1 diabetes (HbA1c 6.4 ± 0.6%) during the 2019 Tour of California. RESULTS In-ride time spent in euglycemia (3.9–10.0 mmol/L glucose) was 63 ± 11%, with a low percentage of time spent in level 1 (3.0–3.9 mmol/L; 0 ± 1% of time) and level 2 (&amp;lt;3.0 mmol/L; 0 ± 0% of time) hypoglycemia over the 7-day race. Riders spent 25 ± 9% of time in level 1 (10.1–13.9 mmol/L) and 11 ± 9% in level 2 (&amp;gt;13.9 mmol/L) hyperglycemia during races. Bolus insulin use was uncommon during races, despite high carbohydrate intake (76 ± 23 g ⋅ h−1). Overnight, the riders spent progressively more time in hypoglycemia from day 1 (6 ± 12% in level 1 and 0 ± 0% in level 2) to day 7 (12 ± 12% in level 1 and 2 ± 4% in level 2) (χ2[1] &amp;gt; 4.78, P &amp;lt; 0.05). CONCLUSIONS Professional cyclists with type 1 diabetes have excellent in-race glycemia, but significant hypoglycemia during recovery overnight, throughout a 7-day stage race.
SINGLE PROCEDURE SUCCESS RATE OF RADIOFREQUENCY CATHETER ABLATION OF PERSISTENT ATRIAL FIBRILLATION RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL REGISTRY
Authors: Domenico Giovanni Della Rocca, Luigi Di Biase, Nicola Tarantino, Chintan Trivedi, Mohamed Bassiouny, Amin Al-Ahmad, Sanghamitra Mohanty, Ghulam Murtaza, Krishna Akella, Jorge Romero, David Felipe Briceno, Ashkan Ahmadian-Tehrani, John Burkhardt, Rodney Horton, Carola Gianni, Dhanunjaya R. Lakkireddy, G. Gallinghouse, Andrea Natale
Journal: Journal of the American College of Cardiology (2020)